<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618223</url>
  </required_header>
  <id_info>
    <org_study_id>Dapa-Rhemis</org_study_id>
    <nct_id>NCT05618223</nct_id>
  </id_info>
  <brief_title>Dapagliflozin Effect on Rheumatic Mitral Stenosis</brief_title>
  <acronym>Dapa-Rhemis</acronym>
  <official_title>Dapagliflozin Effect on Rheumatic Mitral Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitas Sebelas Maret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitas Sebelas Maret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatic mitral stenosis remains a health problem in developing countries. Progressive&#xD;
      fibrosis of the valves and myocardium is the main pathophysiology that plays an important&#xD;
      role. Dapagliflozin has various beneficial effects on the heart by reducing fibrosis,&#xD;
      reducing inflammation, and improving patient quality of life. However, the role of this&#xD;
      therapy is unknown in patients with rheumatic mitral stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label study on Rheumatic Mitral Stenosis patients, carried out at&#xD;
      Sebelas Maret University Hospital Sukoharjo, Panti Rahayu Hospital Purwodadi, and Permata&#xD;
      Bunda Hospital Purwodadi. Researchers divided 36 Rheumatic Mitral Stenosis patients&#xD;
      sequentially into two groups, the first was the dapagliflozin group which would receive&#xD;
      dapagliflozin 10 mg once a day and standard treatment. And the second group will only get&#xD;
      standard treatment. Each patient will be examined on PICP, MMP-1, MMP-1/TIMP-1 ratio, TGF-β,&#xD;
      Net atrioventricular compliance index, NT-pro BNP, and Kansas City Cardiomyopathy&#xD;
      Questionnaire on day 1 and one month after the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pre and post-test design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvements of Biomolecular Parameters</measure>
    <time_frame>4 weeks</time_frame>
    <description>PICP in pg/ml, MMP-1 in pg/ml, MMP-1/TIMP-1 ratio, TGF-β in pg/ml, NT-ProBNP in pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvements of Clinical Parameters</measure>
    <time_frame>4 weeks</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire (KCCQ) scores are scaled 0-100 (the higher score indicates a better condition)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvements of Echocardiography Parameters</measure>
    <time_frame>4 weeks</time_frame>
    <description>Net atrioventricular compliance in mL/mmHG, mitral valve gradient in mmHg and mPAP in mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events</measure>
    <time_frame>4 weeks</time_frame>
    <description>All cause cardiac rehospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Rheumatic Heart Disease</condition>
  <condition>Heart Failure</condition>
  <condition>Mitral Stenosis</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10 mg once a day and standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Dapagliflozin 10 mg once daily in addition to standard therapy</description>
    <arm_group_label>Dapagliflozin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe mitral stenosis by echocardiographic examination of the planimetric method with&#xD;
             morphology that supports the etiology of rheumatic&#xD;
&#xD;
          -  Heart failure in functional class II-III&#xD;
&#xD;
          -  Dapagliflozin naive&#xD;
&#xD;
        Exception Criteria:&#xD;
&#xD;
          -  Other significant valve diseases&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Unstable hemodynamic conditions including cardiogenic shock&#xD;
&#xD;
          -  history of mitral valve replacement/repair or mitral balloon valvuloplasty&#xD;
&#xD;
          -  history of hypoglycemia&#xD;
&#xD;
          -  eGFR below 25 mmHg&#xD;
&#xD;
          -  diffuse pulmonary fibrosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>An Aldia Asrial, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitas Sebelas Maret</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>An Aldia Asrial, MD</last_name>
    <phone>+6281229663174</phone>
    <email>aaldiaa8@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anggit Pudjiastuti, MD</last_name>
    <phone>+6285225036705</phone>
    <email>anggituy@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sebelas Maret University Hospital</name>
      <address>
        <city>Sukoharjo</city>
        <state>Central Java</state>
        <zip>58192</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>An Aldia Asrial, MD</last_name>
      <phone>+6281229663174</phone>
      <email>aaldiaa8@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Banerjee T, Mukherjee S, Ghosh S, Biswas M, Dutta S, Pattari S, Chatterjee S, Bandyopadhyay A. Clinical significance of markers of collagen metabolism in rheumatic mitral valve disease. PLoS One. 2014 Mar 6;9(3):e90527. doi: 10.1371/journal.pone.0090527. eCollection 2014.</citation>
    <PMID>24603967</PMID>
  </reference>
  <reference>
    <citation>Banerjee T, Mukherjee S, Biswas M, Dutta S, Chatterjee S, Ghosh S, Pattari S, Nanda NC, Bandyopadhyay A. Circulating carboxy-terminal propeptide of type I procollagen is increased in rheumatic heart disease. Int J Cardiol. 2012 Apr 5;156(1):117-9. doi: 10.1016/j.ijcard.2012.01.026. Epub 2012 Feb 1. No abstract available.</citation>
    <PMID>22305814</PMID>
  </reference>
  <reference>
    <citation>Lin YW, Chen CY, Shih JY, Cheng BC, Chang CP, Lin MT, Ho CH, Chen ZC, Fisch S, Chang WT. Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation-Induced Myocardial Dysfunction. J Am Heart Assoc. 2021 Apr 6;10(7):e019274. doi: 10.1161/JAHA.120.019274. Epub 2021 Mar 20.</citation>
    <PMID>33749310</PMID>
  </reference>
  <reference>
    <citation>Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, Drazner MH, Fong MW, Givertz MM, Gordon RA, Jermyn R, Katz SD, Lamba S, Lanfear DE, LaRue SJ, Lindenfeld J, Malone M, Margulies K, Mentz RJ, Mutharasan RK, Pursley M, Umpierrez G, Kosiborod M. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 2019 Oct 29;140(18):1463-1476. doi: 10.1161/CIRCULATIONAHA.119.042929. Epub 2019 Sep 16.</citation>
    <PMID>31524498</PMID>
  </reference>
  <reference>
    <citation>Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr;31(2):119-132. doi: 10.1007/s10557-017-6725-2.</citation>
    <PMID>28447181</PMID>
  </reference>
  <reference>
    <citation>Li G, Zhao C, Fang S. SGLT2 promotes cardiac fibrosis following myocardial infarction and is regulated by miR-141. Exp Ther Med. 2021 Jul;22(1):715. doi: 10.3892/etm.2021.10147. Epub 2021 May 3.</citation>
    <PMID>34007324</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitas Sebelas Maret</investigator_affiliation>
    <investigator_full_name>An Aldia Asrial</investigator_full_name>
    <investigator_title>An Aldia Asrial, MD, FIHA (Principal investigator)</investigator_title>
  </responsible_party>
  <keyword>rheumatic heart disease</keyword>
  <keyword>mitral stenosis</keyword>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Heart Disease</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Mitral Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

